Haixin Co., Ltd. (600851.SH) announced semi-annual results, with net profit of 129 million yuan to mother, an increase of 20.30% over the previous year

Zhitongcaijing · 3d ago

According to Zhitong Finance App News, Haixin Co., Ltd. (600851.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 312 million yuan, a year-on-year decrease of 16.22%; net profit attributable to shareholders of listed companies was 129 million yuan, an increase of 20.30%; deducted non-net profit of 127 million yuan, an increase of 21.14%; and basic earnings per share were 0.1071 yuan.

During the reporting period, the domestic pharmaceutical industry showed a trend of “basing valuations, reshaping policies, and breaking the game through innovation”. Biomedicine has been established as an “emerging pillar industry”; new anti-corruption regulations have been implemented, and the full-chain intelligent supervision system is being improved; collection adheres to the “no collection of new drugs” principle, the 12th batch of national procurement is progressing steadily, and price control of pharmaceutical consumables has been fully initiated. In this context, the company holds pharmaceutical companies firm in their development ideas, implements development plans, and consolidates the quality of operations. On the sales side, due to drug collection policies and market factors, etc., the company's product sales have declined; in terms of research and development, the consistency evaluation of the two generic drug types is in the CDE review and approval stage, and post-marketing research work on core varieties is progressing steadily.